{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T02:10:40Z","timestamp":1777774240740,"version":"3.51.4"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006322","name":"Institute for Molecular Science","doi-asserted-by":"publisher","award":["LA\/P\/0056\/2020 https:\/\/doi.org\/10.54499\/LA\/P\/0056\/2020"],"award-info":[{"award-number":["LA\/P\/0056\/2020 https:\/\/doi.org\/10.54499\/LA\/P\/0056\/2020"]}],"id":[{"id":"10.13039\/501100006322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006507","name":"Funda\u00e7\u00e3o Oswaldo Cruz","doi-asserted-by":"publisher","award":["31010016"],"award-info":[{"award-number":["31010016"]}],"id":[{"id":"10.13039\/501100006507","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008331","name":"Universidade Federal do Rio de Janeiro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ijbiomac.2026.150723","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T16:02:02Z","timestamp":1770307322000},"page":"150723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Synthesis and functional characterization of a recombinant HIV-1 reverse transcriptase variant carrying twelve drug-resistance mutations as a platform for antiretroviral screening"],"prefix":"10.1016","volume":"349","author":[{"given":"Tarcizio Jos\u00e9","family":"dos Santos-Filho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ot\u00e1vio Augusto","family":"Chaves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e1rbara Martins","family":"Cordeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Frederico Leite","family":"Fontes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio Alberto","family":"Mignaco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2026.150723_bb0005","series-title":"Global HIV & AIDS Statistics \u2014 Fact Sheet","author":"UNAIDS","year":"2024"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150723_bb0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3947\/ic.2020.0100","article-title":"An overview of human immunodeficiency virus-1 antiretroviral drugs: general principles and current status","volume":"53","author":"Shin","year":"2021","journal-title":"Infect Chemother."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.150723_bb0015","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.3390\/ijms25073659","article-title":"A review of FDA-approved anti-HIV-1 drugs, anti-Gag compounds, and potential strategies for HIV-1 eradication","volume":"25","author":"Sever","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.150723_bb0020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.sbi.2019.11.011","article-title":"Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance","volume":"61","author":"Xavier Ruiz","year":"2020","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.150723_bb0025","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1006\/jmbi.2001.4904","article-title":"The ribonuclease H activity of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2 is affected by the thumb subdomain of the small protein subunits","volume":"311","author":"Sevilya","year":"2001","journal-title":"J. Mol. Biol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150723_bb0030","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MDNA3-0027-2014","article-title":"Reverse transcription of retroviruses and LTR retrotransposons","volume":"3","author":"Hughes","year":"2015","journal-title":"Microbiol. Spectr."},{"issue":"35","key":"10.1016\/j.ijbiomac.2026.150723_bb0035","doi-asserted-by":"crossref","first-page":"21274","DOI":"10.1073\/pnas.2009415117","article-title":"How a B family DNA polymerase has been evolved to copy RNA","volume":"117","author":"Choi","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"13","key":"10.1016\/j.ijbiomac.2026.150723_bb0040","doi-asserted-by":"crossref","first-page":"7915","DOI":"10.1021\/acscatal.1c01493","article-title":"The role of conserved residues in the DEDDh motif: the proton-transfer mechanism of HIV-1 RNase H","volume":"11","author":"D\u00fcrr","year":"2021","journal-title":"ACS Catal."},{"issue":"18","key":"10.1016\/j.ijbiomac.2026.150723_bb0045","doi-asserted-by":"crossref","first-page":"11687","DOI":"10.1093\/nar\/gku819","article-title":"Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence","volume":"42","author":"Schauer","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.150723_bb0050","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1073\/pnas.1719746115","article-title":"Structure of HIV-1 reverse transcriptase cleaving RNA in an RNA\/DNA hybrid","volume":"115","author":"Tian","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.150723_bb0055","first-page":"419","article-title":"A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase","volume":"96","author":"Meyer","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"45","key":"10.1016\/j.ijbiomac.2026.150723_bb0060","doi-asserted-by":"crossref","first-page":"15908","DOI":"10.1021\/bi981200e","article-title":"Phenotypic mechanism of HIV-1 resistance to 3\u2032-azido-3\u2032-deoxythymidine (AZT): increased polymerase processivity and enhanced sensitivity to pyrophosphate","volume":"37","author":"Arion","year":"1998","journal-title":"Biochemistry"},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.150723_bb0065","first-page":"1128","article-title":"Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors","volume":"62","author":"Sluis-Cremer","year":"2005","journal-title":"Cell. Mol. Life Sci."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.150723_bb0075","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1016\/j.bmc.2010.03.030","article-title":"Design of potential reverse transcriptase inhibitor containing isatin nucleus using molecular modeling studies","volume":"18","author":"Pawar","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2026.150723_bb0080","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.coph.2020.10.009","article-title":"Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief overview of clinically approved drugs and combination regimens","volume":"54","author":"Vanangamudi","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.150723_bb0085","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/17425255.2019.1673367","article-title":"Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment","volume":"15","author":"Wang","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.150723_bb0090","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/COH.0000000000000471","article-title":"Doravirine: a review","volume":"13","author":"Colombier","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"1\u20132","key":"10.1016\/j.ijbiomac.2026.150723_bb0095","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.virusres.2007.12.021","article-title":"HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo","volume":"134","author":"Martinez-Picado","year":"2008","journal-title":"Virus Res."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.150723_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002251","article-title":"Extremely high mutation rate of HIV-1 in vivo","volume":"13","author":"Cuevas","year":"2015","journal-title":"PLoS Biol."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.150723_bb0105","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1046\/j.1469-0691.2003.00730.x","article-title":"New patterns of HIV-1 resistance during HAART","volume":"9","author":"Fumero","year":"2003","journal-title":"Clin. Microbiol. Infect."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.150723_bb0110","first-page":"642","article-title":"2014 update of the drug resistance mutations in HIV-1","volume":"22","author":"Wensing","year":"2016","journal-title":"Top. Antivir. Med."},{"issue":"21","key":"10.1016\/j.ijbiomac.2026.150723_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27217538","article-title":"Identification of boronate-containing diarylpyrimidine derivatives as novel HIV-1 non-nucleoside reverse transcriptase inhibitors","volume":"27","author":"Feng","year":"2022","journal-title":"Molecules"},{"issue":"23","key":"10.1016\/j.ijbiomac.2026.150723_bb0120","doi-asserted-by":"crossref","first-page":"1560826","DOI":"10.1021\/acs.jmedchem.2c00576","article-title":"Lead optimization and avoidance of metabolic-perturbing motif developing novel diarylpyrimidines as potent HIV-1 NNRTIs","volume":"65","author":"Sun","year":"2022","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.150723_bb0125","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/S2666-5247(20)30006-9","article-title":"Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report","volume":"1","author":"Puertas","year":"2020","journal-title":"Lancet Microbe."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150723_bb0130","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1128\/AAC.01032-06","article-title":"A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors","volume":"51","author":"Zhang","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.150723_bb0135","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1006\/jmbi.1997.1427","article-title":"Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions","volume":"274","author":"Maga","year":"1997","journal-title":"J. Mol. Biol."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.150723_bb0140","doi-asserted-by":"crossref","first-page":"7894","DOI":"10.1128\/jvi.70.11.7894-7899.1996","article-title":"Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients","volume":"70","author":"Havlir","year":"1996","journal-title":"J. Virol."},{"issue":"21","key":"10.1016\/j.ijbiomac.2026.150723_bb0145","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.3390\/molecules27217348","article-title":"Me-better drug design based on nevirapine and mechanism of molecular interactions with Y188C mutant HIV-1 reverse transcriptase","volume":"27","author":"Wang","year":"2022","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150723_bb0150","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/00042560-199702010-00006","article-title":"HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine","volume":"14","author":"Demeter","year":"1997","journal-title":"J. Acquir. Immune Defic. Syndr. Hum. Retrovirol."},{"issue":"6664","key":"10.1016\/j.ijbiomac.2026.150723_bb0155","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/34571","article-title":"A new classification for HIV-1","volume":"391","author":"Berger","year":"1998","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.150723_bb0160","first-page":"138","article-title":"Update of the drug resistance mutations in HIV-1","volume":"16","author":"Johnson","year":"2008","journal-title":"Top. HIV Med."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150723_bb0165","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/QAD.0b013e328011e691","article-title":"HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance","volume":"21","author":"Shafer","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.ijbiomac.2026.150723_bb0170","first-page":"22","article-title":"Preparation of calcium competent Escherichia coli and heat-shock transformation","author":"Chang","year":"2017","journal-title":"JEMI Methods"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150723_bb0175","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.antiviral.2007.08.006","article-title":"The dolabellane diterpene dolabelladienetriol is a typical noncompetitive inhibitor of HIV-1 reverse transcriptase enzyme","volume":"77","author":"Cirne-Santos","year":"2008","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150723_bb0180","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ejmech.2008.02.047","article-title":"Synthesis, HIV-RT inhibitory activity and SAR of 1-benzyl-1H-1,2,3-triazole derivatives of carbohydrates","volume":"44","author":"da Silva","year":"2009","journal-title":"Eur. J. Med. Chem."},{"issue":"27","key":"10.1016\/j.ijbiomac.2026.150723_bb0185","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1039\/B517914A","article-title":"Advances in methods and algorithms in a modern quantum chemistry program package","volume":"8","author":"Shao","year":"2006","journal-title":"Phys. Chem. Chem. Phys."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150723_bb0190","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150723_bb0195","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nsmb.2223","article-title":"HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism","volume":"19","author":"Das","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.150723_bb0200","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1073\/pnas.92.4.1222","article-title":"The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1","volume":"92","author":"Rodgers","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"W1","key":"10.1016\/j.ijbiomac.2026.150723_bb0205","doi-asserted-by":"crossref","first-page":"W296","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL homology modelling of protein structures and complexes","volume":"46","author":"Waterhouse","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.150723_bb0210","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1006\/jmbi.1996.0897","article-title":"Development and validation of a genetic algorithm for flexible docking","volume":"267","author":"Jones","year":"1997","journal-title":"J. Mol. Biol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.150723_bb0215","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1006\/jmbi.2001.4988","article-title":"Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors","volume":"312","author":"Ren","year":"2001","journal-title":"J. Mol. Biol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150723_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/wcms.1298","article-title":"Using PyMOL as a platform for computational drug design","volume":"7","author":"Yuan","year":"2017","journal-title":"WIREs Comput. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150723_bb0225","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28389","article-title":"Analysis of mutational history of multidrug-resistant genotypes with a mutagenetic tree model","volume":"95","author":"Pirkl","year":"2023","journal-title":"J. Med. Virol."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.150723_bb0230","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1021\/jm0211117","article-title":"N-aminoimidazole derivatives inhibiting retroviral replication via a yet unidentified mode of action","volume":"46","author":"Lagoja","year":"2003","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.ijbiomac.2026.150723_bb0235","first-page":"8588","article-title":"Subunit-selective mutagenesis identifies residues involved in the dimerization of HIV-1 reverse transcriptase","volume":"263","author":"Le Grice","year":"1988","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150723_bb0240","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbapap.2005.06.005","article-title":"How to study proteins by circular dichroism","volume":"1751","author":"Kelly","year":"2005","journal-title":"Biochim. Biophys. Acta, Proteins Proteomics"},{"issue":"16","key":"10.1016\/j.ijbiomac.2026.150723_bb0245","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1002\/j.1460-2075.1996.tb00816.x","article-title":"Human immunodeficiency virus type 1 reverse transcriptase: role of Tyr115 in deoxynucleotide binding and misinsertion fidelity of DNA synthesis","volume":"15","author":"Mart\u00edn-Hern\u00e1ndez","year":"1996","journal-title":"EMBO J."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.150723_bb0250","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1046\/j.1432-1327.2000.01272.x","article-title":"Fidelity analysis of HIV-1 reverse transcriptase mutants with an altered amino-acid sequence at residues Leu74, Glu89, Tyr115, Tyr183 and Met184","volume":"267","author":"Jonckheere","year":"2000","journal-title":"Eur. J. Biochem."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.150723_bb0255","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1074\/jbc.M411559200","article-title":"Mechanistic insights into the suppression of drug resistance by human immunodeficiency virus type 1 reverse transcriptase using alpha-boranophosphate nucleoside analogs","volume":"280","author":"Deval","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.150723_bb0260","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jmb.2008.10.071","article-title":"Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition","volume":"385","author":"Sarafianos","year":"2009","journal-title":"J. Mol. Biol."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.150723_bb0265","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1128\/JVI.74.8.3579-3585.2000","article-title":"The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis","volume":"74","author":"G\u00f6tte","year":"2000","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.150723_bb0270","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1128\/JVI.05767-11","article-title":"A role of template cleavage in reduced excision of chain-terminating nucleotides by human immunodeficiency virus type 1 reverse transcriptase containing the M184V mutation","volume":"86","author":"Acosta-Hoyos","year":"2012","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.150723_bb0275","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3390\/v16091392","article-title":"Treatment management challenges in na\u00efve and experienced HIV-1-infected individuals carrying the M184V mutation","volume":"16","author":"Mimtsoudis","year":"2024","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.150723_bb0280","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2174\/157016209788347958","article-title":"Characterization of HIV-1 enzyme reverse transcriptase inhibition by the compound 6-chloro-1,4-dihydro-4-oxo-1-(beta;-d-ribofuranosyl) quinoline-3-carboxylic acid through kinetic and in silico studies","volume":"7","author":"Souza","year":"2009","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.ijbiomac.2026.150723_bb0285","first-page":"1","article-title":"Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists","volume":"46","author":"Copeland","year":"2005","journal-title":"Methods Biochem. Anal."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150723_bb0290","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1042\/bj0550170","article-title":"The determination of enzyme inhibitor constants","volume":"55","author":"Dixon","year":"1953","journal-title":"Biochem. J."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.150723_bb0295","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1042\/bj1390715","article-title":"The direct linear plot. A new graphical procedure for estimating enzyme kinetic parameters","volume":"139","author":"Eisenthal","year":"1974","journal-title":"Biochem. J."},{"key":"10.1016\/j.ijbiomac.2026.150723_bb0300","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2217\/hiv.09.3","article-title":"Promising novel compounds for generation of new anti-HIV-RT therapeutic drugs","author":"Souza","year":"2009","journal-title":"HIV Therapy (Print)."},{"key":"10.1016\/j.ijbiomac.2026.150723_bb0305","series-title":"Reverse Transcriptase Inhibitors in HIV\/AIDS Therapy","volume":"Vol. 1","author":"Skrown","year":"2006"},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.150723_bb0310","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0969-2126(00)00513-X","article-title":"Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase","volume":"8","author":"Ren","year":"2000","journal-title":"Structure"},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.150723_bb0315","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1021\/jm061117m","article-title":"Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases","volume":"50","author":"Ren","year":"2007","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150723_bb0320","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.antiviral.2009.09.008","article-title":"Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009)","volume":"85","author":"de B\u00e9thune","year":"2010","journal-title":"Antiviral Res."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.150723_bb0325","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1128\/AAC.44.9.2475-2484.2000","article-title":"Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy","volume":"44","author":"Bacheler","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.150723_bb0330","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1128\/AAC.00870-09","article-title":"Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance","volume":"54","author":"Gupta","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150723_bb0335","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jac\/dkt316","article-title":"Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing","volume":"69","author":"Melikian","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijbiomac.2026.150723_bb0340","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.virol.2015.05.020","article-title":"Mutations in human immunodeficiency virus type 1 reverse transcriptase that make it sensitive to degradation by the viral protease in virions are selected against in patients","volume":"484","author":"Dunn","year":"2015","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150723_bb0345","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.antiviral.2007.06.002","article-title":"NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine","volume":"76","author":"Paolucci","year":"2007","journal-title":"Antivir. Res."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150723_bb0350","first-page":"67","article-title":"HIV-1 drug resistance mutations: an updated framework for the second decade of HAART","volume":"10","author":"Shafer","year":"2008","journal-title":"AIDS Rev."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.150723_bb0355","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1128\/AAC.05487-11","article-title":"Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility","volume":"56","author":"Melikian","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.150723_bb0360","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1468-1293.2004.00243.x","article-title":"Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens","volume":"5","author":"Lanier","year":"2004","journal-title":"HIV Med."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.150723_bb0365","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/01.inf.0000243211.36690.d5","article-title":"Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy","volume":"25","author":"Averbuch","year":"2006","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.150723_bb0370","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1128\/AAC.47.11.3377-3383.2003","article-title":"Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase","volume":"47","author":"Diallo","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"14","key":"10.1016\/j.ijbiomac.2026.150723_bb0375","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1128\/JVI.74.14.6262-6268.2000","article-title":"Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection","volume":"74","author":"Frost","year":"2000","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.150723_bb0380","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/135965350100600303","article-title":"Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy","volume":"6","author":"Mouroux","year":"2001","journal-title":"Antivir. Ther."},{"issue":"18","key":"10.1016\/j.ijbiomac.2026.150723_bb0385","doi-asserted-by":"crossref","first-page":"11952","DOI":"10.1128\/JVI.79.18.11952-11961.2005","article-title":"Virion instability of human immunodeficiency virus type 1 reverse transcriptase demonstrated that recombinant p66\/p66 homodimers exhibit enzymatic activities (DNA polymerase and RNase H) comparable to p66\/p51 heterodimers","volume":"79","author":"Abram","year":"2005","journal-title":"J. Virol."},{"issue":"36","key":"10.1016\/j.ijbiomac.2026.150723_bb0390","doi-asserted-by":"crossref","first-page":"25988","DOI":"10.1016\/S0021-9258(18)35706-5","article-title":"Mechanism and fidelity of HIV reverse transcriptase","volume":"267","author":"Kati","year":"1992","journal-title":"J. Biol. Chem."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026006495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026006495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:40:13Z","timestamp":1777484413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026006495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":77,"alternative-id":["S0141813026006495"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.150723","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and functional characterization of a recombinant HIV-1 reverse transcriptase variant carrying twelve drug-resistance mutations as a platform for antiretroviral screening","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.150723","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"150723"}}